LifeCannMD

AUGUST 2, 2024

Research has indicated that cannabinoids might have antitumor properties. There is growing interest in the use of topical cannabinoid formulations for skin cancer treatment. It has gained attention for its potential therapeutic effects, particularly in the context of cancer treatment, including skin cancer, and other skin disorders.

Clinical Trials 52

Clinical Trials Cannabinoids Research and Development Concentrates 52

Cannabis Law Report

AUGUST 10, 2021

As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021.

Clinical Trials 105

Clinical Trials Research and Development Therapy Treatment 105

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. ABOUT ANANDA SCIENTIFIC.

Clinical Trials 52

Clinical Trials Treatment Research and Development Media 52

Cannabis Law Report

MARCH 30, 2019

Ministry of Health, Labor and Welfare officials recently announced the trials during a meeting of the Okinawa-Northern Task Force, a research and development agency. Epidiolex was crafted as a treatment for two forms of childhood epilepsy. Japanese officials approve Epidiolex for clinical trials.

Clinical Trials 45

Clinical Trials Research and Development Epilepsy Environment 45

Cannabis Law Report

JULY 6, 2021

GH Research, a Dublin-based company studying the potential of 5-MeO-DMT for the treatment of psychiatric and neurological disorders, is now listing its stock on the Nasdaq under the symbol “GHRS” after opening for trading on Friday, July 2 at $22. The financing was co-led by RA Capital and RTW Investments, LP, U.S.

Clinical Trials 96

Clinical Trials Research and Development Treatment Therapy 96

Cannabis Law Report

DECEMBER 27, 2019

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

AUGUST 13, 2021

Derived from Salvia divinorum, SalA is a unique non-nitrogenous agonist of the kappa-opioid receptor (KOR) with potential use in treatment-resistant depression (TRD), substance use disorder (SUD) and pain. Clinically, there are published reports of the potential benefits of Salvia divinorum in the treatment of TRD. BERLIN, Aug.

Conditions 105

Conditions Research and Development Clinical Trials Treatment 105

Cannabis Law Report

OCTOBER 15, 2021

(USOTC: PAOG) cited a British Medical Journal case study report published today on the effectiveness of CBD in the treatment of lung cancer and COPD as validation of PAOG’s ongoing research and development of its own respiratory disorder treatment under the name RespRx. 9,199,960).

Treatment 52

Treatment Research and Development CBD eCommerce 52

Veriheal

JULY 16, 2020

The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. Research is Limited Due to Many Obstacles.

Research and Development 97

Research and Development Clinical Trials Treatment Compliance 97

Cannabis Law Report

JULY 6, 2021

This collaboration is intended to include research into COMP360 psilocybin therapy and other novel therapies that may be developed by COMPASS in areas of unmet need such as depression, post-traumatic stress disorder (PTSD) and anorexia. This is a really exciting prospect and has the potential to change people’s lives for the better.”.

Research and Development 98

Research and Development Clinical Trials Therapy Patients 98

MGC Pharma

FEBRUARY 20, 2018

The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Project CBD

OCTOBER 26, 2023

The vast majority of the existing research is on how specific cannabinoids kill cancer, but a growing body of work is revealing how the entourage of compounds found in whole-plant cannabis kills cancer. Without increased blood flow, the tumor does not have enough nutrition to sustain its development.

Research and Development 343

Research and Development Cannabinoids Terpenes Pharmaceutical 343

Cannabis Law Report

SEPTEMBER 29, 2021

This trial is being led by principal investigators Edythe London, Ph.D., Funding for this trial is from the National Institute on Drug Abuse (NIDA). “We We are excited to be moving forward with this trial in conjunction with ANANDA ,” said Dr. De La Garza. ABOUT ANANDA SCIENTIFIC.

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma’s objective is to create and leverage a proprietary drug development platform in collaboration with an artificial intelligence and machine learning group to identify new bioactive compounds within the cannabis plant that interact with certain gene targets responsible for specific disease states and conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JUNE 30, 2021

In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials. For example, research shows that primary care physicians misdiagnosed 65.9% MedXtractor Corp.’s Psychedelics Provide a Solution.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Puff Puff Post

MARCH 10, 2020

“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Advance to FDA IND-enabling studies to support human clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.

Research and Development 112

Research and Development Data THC Clinical Trials 112

Cannabis Law Report

JULY 27, 2021

.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. It is our hope that this study may embolden clinicians and patients to effectively partner in considering these treatments.”.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

SpeedWeed

JULY 23, 2021

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Silo Pharma Inc. Looking to the Future.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Cannabis Law Report

FEBRUARY 9, 2022

Cybin plans to submit a clinical trial application for a pilot study of CYB004 in the second quarter of calendar year 2022 and expects to initiate the pilot study in the third quarter of calendar year 2022.

Treatment 52

Treatment Clinical Trials Research and Development 52

LifeCannMD

AUGUST 2, 2024

Medical Marijuana is increasingly being considered as a potential treatment for severe migraines. Research on the effectiveness of medical marijuana for migraines is still in the early stages, but some studies and anecdotal evidence suggest it can be beneficial for some individuals. Migraines are often linked with inflammation.

Clinical Trials 52

Clinical Trials Marijuana Research and Development Cannabinoids 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

MMJ Recs

JULY 9, 2024

Traditional treatments, while helpful to some extent, often come with limitations and side effects that can further burden individuals already dealing with a debilitating disease. Medical marijuana has emerged as a promising alternative treatment option for managing symptoms associated with MS.

Marijuana 111

Marijuana Treatment Cannabinoids Patients 111

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Veriheal

FEBRUARY 9, 2023

Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. There is still much yet to learn about how psilocybin can work in a clinical setting.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

LifeCannMD

FEBRUARY 27, 2024

Inflammation in the brain is thought to contribute to the development and persistence of seizures. The most compelling evidence of the effectiveness of Medical Marijuana in treating epilepsy comes from clinical trials. Medical Marijuana has been shown to have anti-inflammatory properties.

Clinical Trials 59

Clinical Trials Epilepsy Marijuana Research and Development 59

Cannabis Law Report

AUGUST 26, 2022

Several companies are facilitating the development of this product. More research is still needed to explore this uncharted territory. CBD has been suggested to act as a treatment for sclerosis symptoms, as well as epilepsy among children. However, deeper research is needed to better understand its roles. Flashing lights.

Epilepsy 52

Epilepsy Treatment CBD Sleep 52

Cannabis Law Report

SEPTEMBER 22, 2021

This change would mean it would be easier to run trials on its use in mental health treatments. The Prime Minister had already approved the rescheduling of psilocybin for exploring its potential as a treatment for depression, which he informed Mr Blunt in a meeting in May.

Research and Development 52

Research and Development Clinical Trials Treatment History 52

Cannabis Law Report

SEPTEMBER 10, 2021

The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

DECEMBER 9, 2021

Nue Life is donating $50,000 to MAPS and $10,000 to the Ketamine Research Foundation. “We believe it is the responsibility of psychedelic-therapy companies to provide material support to the life-changing research being done in the space, which has made our work possible. . MIAMI , Dec.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

MARCH 25, 2020

OTCQB: AXIM) (“AXIM® Biotech” or “AXIM”) has completed the acquisition of leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”). Valencia has stewarded Sapphire in the development of its unique patent-pending pipeline. CEO Dr. Stuart Titus.

Research and Development 59

Research and Development Supply Chain Pharmaceutical Clinical Trials 59

SpeedWeed

AUGUST 16, 2021

Oxford-based startup Beckley Psytech in the United Kingdom announced August 15 that it raised $80 million to ramp up clinical trials and research using a pharmaceutical formulation of ??5-MeO-DMT Clinical studies using psilocybin show huge potential to battle treatment-resistant depression, under the guidance of a therapist.

Research and Development 52

Research and Development Clinical Trials Treatment Conditions 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

MAY 12, 2022

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s). Under the terms of the agreement Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on R&D. May 11, 2022 02:00 AM Eastern Daylight Time.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Puff Puff Post

JANUARY 13, 2020

Now that retailers broadly sell CBD oil, it offers a number of challenges and opportunities to medical researchers. Preliminary Research on CBD Oil. Pharmacies, as more profitable companies, have the resources to research the other cannabinoids present in CBD oil. Cannabidiol As Treatment For Opiate and Alcohol Addiction.

CBD 52

CBD Clinical Trials Research and Development Oil 52